India Caps Trade Margins on 137 Anti-Cancer Drugs to 30%

The National Pharmaceutical Pricing Authority (NPPA) announced on Saturday that it has capped trade margins for 137 non-scheduled anti-cancer drugs at 30%. This regulation, effective from November 9, is anticipated to lead to a significant reduction in retail prices, potentially lowering them by as much as 70%, according to the Ministry of Chemicals and Fertilisers.

This decision follows recommendations from an expert committee formed under the Directorate General of Health Services (DGHS), which included prominent oncologists and medical professionals. The committee's analysis identified these 137 drugs for margin rationalisation, and the NPPA plans to periodically update this list to ensure ongoing relevance and effectiveness.

The NPPA's current initiative builds on a successful pilot program from 2019, where trade margins on 42 anti-cancer medications were similarly capped, resulting in price reductions of up to 90% across various brands. The new measure significantly expands the scope of this initiative, encompassing a broader range of cancer treatments.

Pharmaceutical companies are now required to publish updated price lists on their websites and communicate these changes to retailers and hospitals. Retailers and hospitals must implement the new pricing from November 9 and display the updated rates prominently. Hospitals, which are major purchasers of oncology drugs, are also responsible for ensuring compliance with these new prices on their platforms.

To maintain price stability and ensure patient access to these essential medicines, state drug controllers have been instructed to enforce compliance among manufacturers, dealers, and medical institutions. The NPPA has emphasized the importance of maintaining production levels to avoid any potential shortages, aiming to balance fair pricing with the sustainability of the pharmaceutical industry.